Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference

October 21, 2016

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-footprints-for-neurodegenerative-and-autoimmune-conditions.pdf

Epigenetic signatures and early detection of neurodegenerative diseases.

Salter, M., et. al.,
The Lancet Neurology Conference

October 19, 2016

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-signatures-and-early-detection-of-neurodegenerative-diseases.pdf

Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.

Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

September 15, 2016

http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146797/tatiana.plavina.chromosome.conformation.capture.to.discover.candidate.html?f=m3

Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.

Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

September 14, 2016

http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146441/joyce.joseph.epigenetic.profile.of.chromosome.conformation.signatures.html?f=m3

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.

Jeznach, M.
International Pharmaceutical Industry

April 20, 2016

https://issuu.com/mark123/docs/ipi_march2016_web/45

Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients.

Carini, C., et. al.,
Annual Meeting of the American College of Rheumatology

November 7, 2015

http://acrabstracts.org/abstract/epigenetic-chromosome-conformations-predict-mtx-responsiveness-in-early-rheumatoid-arthritis-patients/

Development of Epigenetic Profiling of ALS Patients with Chromosome Conformation Biomarkers Offers Novel Signatures for Non-invasive Diagnostic and Prognostic Stratifications.

Hunter, E., et. al.,
14th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

November 3, 2015

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSNEALS2015.pdf

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Jakub, JW., et. al.,
Melanoma Research

October 3, 2015

https://www.ncbi.nlm.nih.gov/pubmed/26225582

Chromatin barcodes as biomarkers for melanoma.

Bastonini, E., et. al.,
Pigment Cell Melanoma Research

September 3, 2014

https://www.ncbi.nlm.nih.gov/pubmed/24807349

A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).

Lim, EH., et. al.,
J Clinical Oncology

May 30, 2014

http://meetinglibrary.asco.org/content/133682-144